DOI QR코드

DOI QR Code

Associations of Serum Isoflavone, Adiponectin and Insulin Levels with Risk for Epithelial Ovarian Cancer: Results of a Case-control Study

  • Otokozawa, Seiko (Department of Public Health, Sapporo Medical University School of Health Sciences) ;
  • Tanaka, Ryoichi (Department of Obstetrics and Gynecology, Sapporo Medical University School of Health Sciences) ;
  • Akasaka, Hiroshi (Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Health Sciences) ;
  • Ito, Eiki (Department of Obstetrics and Gynecology, Sapporo Medical University School of Health Sciences) ;
  • Asakura, Sumiyo (Department of Public Health, Sapporo Medical University School of Health Sciences) ;
  • Ohnishi, Hirofumi (Department of Public Health, Sapporo Medical University School of Health Sciences) ;
  • Saito, Shigeyuki (Department of Nursing, Sapporo Medical University School of Health Sciences) ;
  • Miura, Tetsuji (Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Health Sciences) ;
  • Saito, Tsuyoshi (Department of Obstetrics and Gynecology, Sapporo Medical University School of Health Sciences) ;
  • Mori, Mitsuru (Department of Public Health, Sapporo Medical University School of Health Sciences)
  • Published : 2015.07.13

Abstract

Background: The aim of this study was to examine the association of serum isoflavones, adiponectin, and insulin levels with ovarian cancer risk. Materials and Methods: We gathered cases with histologically confirmed epithelial ovarian cancer at Sapporo Medical University Hospital from October 2010 to September 2012. Potential controls were recruited from female inpatients without any history of cancer or diabetes mellitus in different wards of the same hospital over the same period of time. Serum isoflavones, adiponectin, and insulin levels were measured in order to estimate associations with ovarian cancer risk in a case-control study. Data from 71 cases and 80 controls were analyzed with a logistic regression model adjusting for known risk factors. Results: A significant reduction in ovarian cancer risk was observed for the high tertile of serum daidzein level versus the low ($P_{trend}<0.001$). A significant reduction in ovarian cancer risk was also observed for the high tertile of serum glycitein level versus the low ($P_{trend}=0.005$). Furthermore, a significant reduction in ovarian cancer risk was observed for the high tertile of serum adiponectin level versus the low ($P_{trend}=0.004$). Conversely, serum insulin level showed significantly elevated risk for ovarian cancer with the high tertile versus the low $P_{trend}<0.001$). Conclusions: Decreased serum isoflavones levels, such as those for daidzein and glycitein, decreased serum adiponectin levels, and increased serum insulin levels could be shown to be associated with elevated risk of ovarian cancer.

Keywords

Case-control study;isoflavones;insulin;adiponectin

Acknowledgement

Supported by : Ministry of Education, Culture, Sport, Science and Technology in Japan

References

  1. Chang ET, Lee VS, Canchola AJ, et al (2007). Diet and risk of ovarian cancer in the california teachers study cohort. Am J Epidemiol, 165, 802-13. https://doi.org/10.1093/aje/kwk065
  2. Collaborative Group on Epidemiological Studies of Ovarian cancer, Bera V, Doll R, et al (2008). Ovarian cancer and oral contraceptives; collaborative reanalysis of data from 45epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 371, 303-14. https://doi.org/10.1016/S0140-6736(08)60167-1
  3. Coppola D, Saunders B, Fu L, et al (2007). The insulin -like growth factor 1 receptor transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas -receptor expression. Cancer Res, 59, 3264-70.
  4. Dupont J, Reverchon M, Cloix L, et al (2012). Involvement of adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian follicle development and cancer. Int J Dev Biol, 56, 959-67. https://doi.org/10.1387/ijdb.120134jd
  5. Fantuzzi G (2005). Adipose tissue, adipokines, and inflammations. J Allergy Clin Immunol, 115, 911-9. https://doi.org/10.1016/j.jaci.2005.02.023
  6. Giovannucci E (1995). Insulin and colon cancer. Cancer Causes Control, 6, 164-79. https://doi.org/10.1007/BF00052777
  7. Gossner G, Choi M, Tan L, et al (2007). Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol, 105, 23-30. https://doi.org/10.1016/j.ygyno.2006.11.009
  8. Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Association between adiponectin and two different cancers; breast and colon. Asian Pac J Cancer Prev, 13, 395-8. https://doi.org/10.7314/APJCP.2012.13.1.395
  9. Horn-Ross PL, John EM, Canchola AJ, et al (2003). Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst, 95, 1158-64. https://doi.org/10.1093/jnci/djg015
  10. Kaaks R, Toniolo P, Akhmedkhanov A, et al (2000). Serum C-peptide, insulin -like growth factor (IGF)-1, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst, 92, 1592-600. https://doi.org/10.1093/jnci/92.19.1592
  11. Lee AH, Su D, Pasalich M, et al (2014). Soy and isoflavone intake associated with reduced risk of ovarian cancer in southern Chinese women. Nutr Res, 34, 302-7. https://doi.org/10.1016/j.nutres.2014.02.005
  12. Ayyildiz T, Dolar E, Ugras N, et al, (2014). Association of adiponectin receptor (Adipo-R1/R2) expression and colorectal cancer. Asian Pacific J Cancer Prev, 15, 9385-90. https://doi.org/10.7314/APJCP.2014.15.21.9385
  13. Brokaw J, Katsaros D, Wiley A, et al (2007). IGF-1 in epithelial ovarian cancer and its role in disease progression. Growth Factors, 25, 346-54. https://doi.org/10.1080/08977190701838402
  14. Lee MM, Gomez SL, Chang JS, et al (2003). Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev, 12, 665-8.
  15. Lihn AS, Pedersen SB, Richelsen B (2005). Adiponectin; action, regulation and association to insulin sensitivity. Obes Rev, 6, 13-21. https://doi.org/10.1111/j.1467-789X.2005.00159.x
  16. Luhn P, Fallal CM, Weiss JM, et al (2013). Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev, 22, 1304-12. https://doi.org/10.1158/1055-9965.EPI-13-0258
  17. Lukanova A, Lundin, Toniolo P, et al (2002). Circulating levels of insulin-like growth -1 and risk of ovarian cancer. Int J Cancer, 101, 549-54. https://doi.org/10.1002/ijc.10613
  18. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  19. Piver MS, Goldberg JM, Tsukada Y, et al (1996). Characteristics of familial ovarian cancer; a report of the first 1,000 Families in the Gilda Rander Familial ovarian cancer registry. Eur J Gynaecol Oncol, 17, 169-76.
  20. Qu X-L, Fang Y, Zhang M, Zhang Y-Z (2014). Phytoestrogen intake and risk of ovarian cancer; a meta-analysis of 10 observational studies. Asian Pac J Cancer Prev, 15, 9085-91. https://doi.org/10.7314/APJCP.2014.15.21.9085
  21. Risch A, Marrett LD, Jain M, et al (1996).Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol, 144, 363-72. https://doi.org/10.1093/oxfordjournals.aje.a008937
  22. Rizzuto I, Behrens RF, Smith LA (2013). Risk of ovarian cancer in women treated ovarian stimulating drugs for infertility. Cochrane Database Syst Rev, 8.
  23. Roberts DL, Dive C, Renehan AG (2010). Biological mechanisms liking obesity and cancer risk; new perspectives. Annu Rev Med, 61, 301-16. https://doi.org/10.1146/annurev.med.080708.082713
  24. Rossi M, Negri E, Lagiou P, et al (2008). Flavonoids and ovarian cancer risk; A case-control study in Italy. Int J Cancer, 123, 895-8. https://doi.org/10.1002/ijc.23549
  25. Rufer CE, Glatt H, Kulling SK (2006). Structural elucidation of hydroxylated metabolites of the isoflavone equol by gas chromatogtaphy-mass spectrometry and high-performance liquid chromatography -mass spectrometry. Drug Metab Dispos, 34, 51-60.
  26. Schoen RE, Tangen CM, Kuller LH, et al (1999). Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst, 91, 1147-54. https://doi.org/10.1093/jnci/91.13.1147
  27. Soslow RA (2008). Histologic subtypes of ovarian carcinoma; an overview. Int J Gynecol Patho, 127, 161-74.
  28. Troisi R, Potischman N, Hoover RN, et al (1997). Insulin and endometrial cancer. Am J Epidemiol, 146, 476-82. https://doi.org/10.1093/oxfordjournals.aje.a009301
  29. Valladares M, Corsini G, Romero C (2014). Association between obesity and ovarian cancer. Rev Med Chil, 142, 593-8. https://doi.org/10.4067/S0034-98872014000500007
  30. Wang XL, Hur HG, Lee JH, et al (2005). Enantioselective synthesis of S equol from dihydro- daidzein by a newly isolated anaerobic human intestinal bacterium. Appl Environ Microbiol, 71, 214-9. https://doi.org/10.1128/AEM.71.1.214-219.2005
  31. Yamamoto S, Sobue T, Kobayashi M, et al (2003). Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst, 95, 906-13. https://doi.org/10.1093/jnci/95.12.906
  32. Zhang M, Xie X, Lee AH, et al (2004). Soy and isoflavone intake are associated with reduced risk of ovarian cancer in Southeast China. Nutr Cancer, 49, 125-30. https://doi.org/10.1207/s15327914nc4902_2

Cited by

  1. Association of isoflavone biomarkers with risk of chronic disease and mortality: a systematic review and meta-analysis of observational studies vol.75, pp.8, 2017, https://doi.org/10.1093/nutrit/nux021
  2. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer vol.16, pp.1, 2018, https://doi.org/10.1186/s12967-018-1489-4